Skip to main content

Table 1 PD-1 signal inhibitors (anti–PD-1 and anti–PD-L1 antibodies) in clinical trials

From: Cancer immunotherapies targeting the PD-1 signaling pathway

Target Agent IgG class Company Approved
PD-1 nivolumab (Opdivo®, BMS-936558, MDX1106) Human IgG4 Bristol-Meyers Squibb/Ono MelanomaU, E, J
Lung cancerU, E, J
Kidney cancerU, J
Hodgkin’s lymphoma U, E, J
Head and neck cancer U
Urothelial cancer U
pembrolizumab (Keytruda®MK-3475, lambrolizumab) Humanized IgG4 Merck MelanomaU, E, J
Lung cancerU, E, J
Head and neck cancerU
pidilizumab (CT-011) Humanized IgG1k Cure Tech  
AMP-224 PD-L2 IgG2a fusion protein Amplimmune/GlaxoSmith Klein  
AMP-514 (MEDI0680) PD-L2 fusion protein Amplimmune/GlaxoSmith Klein  
PDR001 Humanized IgG4 Novartis Pharmaceuticals  
PD-L1 BMS-936559 (MDX1105) Human IgG4 Bristol-Meyers Squibb  
atezolizumab (Tecentriq®, MPDL3280A) Humanized IgG1k Roche/Genentech Urothelial cancerU
Lung cancerU
durvalumab (MEDI4736) Human IgG1k MedImmune/AstraZeneca  
avelumab (MSB0010718C) Human IgG1 Merck Serono/Pfizer  
  1. All antibodies used in clinical trials as of September 1, 2016 were extracted from
  2. Abbreviations: U U.S. Food and Drug Administration (FDA) approved; E European Medicines Agency (EMA) approved, J Japanese Pharmaceutical and Medical Devices Agency (PMDA) approved